Guardant Health Dives After Losing A Patent Dispute; Judge Orders Royalties
Guardant Health shares fell after a judge ruled against the company in a patent dispute and ordered it to pay royalties. The ruling adds a legal-cost and intellectual-property overhang to a business still growing revenue but reporting a -42.4% net margin.
What happened
Guardant Health shares fell after a judge ruled against the company in a patent dispute and ordered it to pay royalties.
The read · Aug 24
The patent ruling moves the risk to the downside for GH, where royalties add pressure to an already loss-making diagnostics business.
Wrong if
The trade is impaired if the royalty obligation is immaterial, the ruling is stayed or reversed on appeal, or the company discloses no meaningful impact to products and cash flow.
CoverageSource: Yahoo Finance · Published here MON, AUG 24 · 3:04 PM ET · 2 outlets in this record · latest listed: Investing.com at 3:04 PM ETHow this is decided →
The chart · GHTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
The ruling follows a patent dispute involving Guardant Health, with the judge ordering royalties after finding against the company. The headline does not provide the royalty amount, the patents involved, the products affected, or the timing of any payments.
The direct exposure is GH, whose FY 2025 revenue was $982.0M, up 32.9% YoY, according to SEC EDGAR data. That growth sits alongside a -42.4% net margin and dilutive EPS of $-3.32, leaving the company financially sensitive to additional obligations.
The next key disclosures are the size and duration of the royalty burden, any impact on product sales or licensing, and whether Guardant appeals the ruling. The market's initial reaction was negative, but the available reporting does not establish the judgment's dollar value or whether operations are materially constrained.
The read, in fullWhy it matters
The legal overhang matters most because GH is already operating at a -42.4% net margin with dilutive EPS of $-3.32, so an unspecified royalty obligation could further delay the path to profitability. Revenue growth of 32.9% YoY and FY 2025 revenue of $982.0M provide a fundamental offset, but the missing judgment amount prevents a larger directional target.
The read above, as written. kept as written · closes shown from AUG 24 on
Next · what would move this
Tactical / 1-2 weeks. Follow to be told when one lands.
Since this story · named here, equal weight · 1D EOD-1.1%
AUG 24 · first close after publicationSEP 4
Price context does not establish that the story caused the move.
▲ The case it holds
GH's FY 2025 revenue grew 32.9% YoY to $982.0M, giving the company a tangible growth engine that could absorb a limited royalty burden.
▼ The case it breaks
The bear case is stronger on the disclosed facts: a patent loss with court-ordered royalties compounds GH's -42.4% net margin and dilutive EPS of $-3.32, while the amount owed remains unknown.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →
STOCK PHOTO · DAVID GUERRERO